Original Article: bit.ly/157b8SR
The landmark study that found preventive use of antiretroviral medicine by a person who is not ?infected with HIV can lower the risk of acquiring the virus from his or her infected partner has yielded data showing that the intervention poses lower risks of later resistance to the drugs than previously thought.
The findings, described in the Jan.13 Journal of Infectious Diseases were the result of testing samples from the Partners PrEP clinical trial for mutations associated with resistance to emtricitabine and tenofovir, the two antiretroviral drugs the trial tested. The trial’s 4758 participants in Kenya and Uganda, who tested negative for HIV and whose sexual partners tested positive for HIV, were randomly assigned to take a combination of the two drugs, tenofovir alone, or a placebo. With significantly fewer HIV infections among participants taking the combination, or tenofovir alone than those taking a placebo, the trial showed, in results released in July 2011, the highly effective preventive benefit of pre-exposure prophylactic — or PrEP — use of antiretroviral drugs.
Full text of article available at link below: bit.ly/157b8SR